Quick answer
What is Orforglipron?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Orforglipron is not a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 8 from trials in people and 4 that do not state what kind of study it is.
The literature search returned 140 records. This site keeps 12 of them, which is 8.6 per cent of what came back.
What it is
Orforglipron is indexed here despite not being a peptide, because the same research literature and the same searches cover it. This site puts it in the Incretin receptor agonists group.
A non-peptide oral GLP-1 receptor agonist; the retrieved records report the structural basis of receptor activation.[1, 2]
Stated in the titles of the cited 2020 Proceedings of the National Academy of Sciences and 2024 Science Translational Medicine papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 8 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 128 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences of the United States of America (2020). pmid:33177239
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Science translational medicine (2024). pmid:39693407